Funding agencies: The study was supported by the Michael J. Fox Foundation for Parkinson's Research Fast Track 2001 Program, the Parkinson's Disease Foundation, and NIH grants R01NS054978 and K24NS60991.
Caffeine consumption and risk of dyskinesia in CALM-PD
Article first published online: 21 JAN 2013
Copyright © 2013 Movement Disorder Society
Volume 28, Issue 3, pages 380–383, March 2013
How to Cite
Wills, A.-M. A., Eberly, S., Tennis, M., Lang, A. E., Messing, S., Togasaki, D., Tanner, C. M., Kamp, C., Chen, J.-F., Oakes, D., McDermott, M. P., Schwarzschild, M. A. and on behalf of the Parkinson Study Group (2013), Caffeine consumption and risk of dyskinesia in CALM-PD. Mov. Disord., 28: 380–383. doi: 10.1002/mds.25319
Relevant conflicts of interest/financial disclosures: The present study is a secondary analysis of the database of a clinical trial, CALM-PD, and its extension study, CALM Cohort, which were sponsored by Pharmacia Corporation (Peapack, NJ) and Boehringer Ingelheim (Ingelheim, Germany). In January 2001 Pharmacia approved an investigator (Michael A. Schwarzschild)–initiated proposal to introduce an add-on caffeine questionnaire to CALM-PD subjects to test our prespecified hypotheses that higher caffeine consumption is associated with lower rates of dyskinesia development and/or disease progression. Neither Pharmacia nor Boehringer Ingelheim provided funding for or otherwise supported or participated in the present study. Anne-Marie A. Wills participates in the Schering-Plough-sponsored clinical trials of Preladenant and has served as a consultant for Accordant (a CVS/Caremark disease management company), for Asubio Pharmaceuticals, and for NanoDerma Ltd. Shirley Eberly has received research support from the NIH, DOD, Michael J Fox Foundation, Parkinson's Disease Foundation, Cephalon, and Lundbeck. Anthony E. Lang has served as an adviser for Abbott, Allon Therapeutics, Astra Zenica, Avanir Pharmaceuticals, Biovail, Boerhinger-Ingelheim, Cephalon, Ceregene, Eisai, GSK, Lundbeck A/S, Medtronic, Merck Serono, Novartis, Santhera, Solvay, and Teva; has received honoraria from Teva; has received grants from the Canadian Institutes of Health Research, Dystonia Medical Research Foundation, Michael J. Fox Foundation, National Parkinson Foundation, and Ontario Problem Gambling Research Centre; received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press; and has served as an expert witness in cases related to the welding industry. Daniel M. Togasaki participated in the Schering-Plough-sponsored open-label extension study of Preladenant. Caroline M. Tanner is an employee of the Parkinson's Institute; serves on the Scientific Advisory Boards of the Michael J. Fox Foundation and the National Spasmodic Dystonia Association; has provided consulting services to Impax Pharmaceuticals and Adamas Pharmaceuticals; has received grant support from the Michael J. Fox Foundation, the Brin Foundation, James and Sharron Clark, the Parkinson's Institute and Clinical Center, the Parkinson's Disease Foundation, USAMRAA (TATRC managed NETRP Program), National Institute of Neurological Disorders and Stroke (NINDS), and the Agency for Healthcare and Research Quality (AHRQ). Cornelia Kamp is supported by research grants from NINDS, the Michael J. Fox Foundation, and the Friedreich's Ataxia Research Alliance. Jiang-Fan Chen has served as a consultant for Kyowa Pharmaceutical, Inc., and Adenosine Therapeutics. David Oakes has received support from the NIH, the Department of Defense, and the Michael J. Fox Foundation for his research into Parkinson's disease and has received an honorarium from Novo Nordisk Inc. for consulting about an unrelated topic. Michael P. McDermott received research grants from the NIH, FDA, CDC, Muscular Dystrophy Association, SMA Foundation, Michael J. Fox Foundation, Boehringer-Ingelheim Pharmaceuticals, Inc., NeuroSearch Sweden AB, and Medivation, Inc., and served as a consultant for the NY State Department of Health, Pfizer, Inc., Smith and Nephew, Inc., Synosia, Inc., Teva Pharmaceutical Industries, Ltd., Impax Pharmaceuticals, and Bioness, Inc.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 21 MAR 2013
- Article first published online: 21 JAN 2013
- Manuscript Accepted: 12 NOV 2012
- Manuscript Revised: 24 OCT 2012
- Manuscript Received: 29 JUN 2012
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.
Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!